GW PHARMA, UPON BEING ASKED ABOUT THE PROCESS FOR EPIDIOLEX
7 November 2018
Families 4 Access made an inquiry to GW Pharmaceuticals, this week, to better understand the process of obtaining Epidiolex. We have been trying to establish what the condition is in terms of access.
The question we posed was: “Given the change in legislation, we are interested to know if the process in which patients receive Epidiolex will have changed? How will they now be issued this medicine, especially now that there is no longer an expert panel?”
Rest assured that GW is doing everything we can to quickly help patients in urgent need and deliver cannabidiol oral solution (CBD) as soon as possible after formal Trust approval.
In response to the Government’s reforms and guidance notes issued on 1 November, we are working closely with health agencies to define appropriate access routes to our CBD. We hope to be able to release further details to specialist clinicians in the coming days.
We appreciate that there is still work to be done. Families 4 Access will feedback accordingly.
Families 4 Access Team